"Bereuen Sie die Entscheidung zur radikalen Prostatektomie?" Das wurden Langzeitüberlebende eines Prostatakarzinoms Jahre nach Entfernung der Vorsteherdrüse gefragt. Die Ergebnisse verraten einiges darüber, worauf es bei Therapieentscheidungen – neben den "harten" medizinischen Fakten – und bei der Risikokommunikation ankommt. Der Urologe Dr. Valentin Meissn ... Show More
Sep 2022
Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation Update
An interview with Dr. Rohan Garje from Miami Cancer Institute in Miami, FL, lead author on "Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation." Dr. Garje reviews the new evidence and the latest recommend ... Show More
8m 6s
Oct 2023
Early-Stage Prostate Cancer: Know Your Treatment Options
Learn what you need to know about early-stage prostate cancer, from risk factors to treatment options and how to tackle their side effects. In this episode, Dr. Diane Reidy-Lagunes is joined by medical oncologist Dr. Dana Rathkopf, radiation oncologist Dr. Sean McBride, and urolo ... Show More
25m 8s
Apr 2024
A Revolution in Immunotherapy for Cervical and Endometrial Cancers
<p class="MsoNormal" style="margin: 11.0pt 0in 11.0pt 0in;"> <span style= "font-size: 12pt; font-family: arial, helvetica, sans-serif;">Doctors James Ferriss, Linda Duska, and Jayanthi Lea discuss the promise and the challenges of targeting the immune system with immune checkpoin ... Show More
26m 18s
Mar 2024
Episode 171: ASCO-GU Top Clinical Data With Pedro Barata
Dr. Pedro Barata, Director of the Clinical Genitourinary Medical Oncology Research Program at UH Seidman Cancer Center, provides an exclusive round-up of the most groundbreaking and practice-changing research unveiled at the ASCO GU 2024 meeting. With expertise and insight, he de ... Show More
46m 7s
Jan 2024
What's New in Prostate Cancer, RCC, and mUC at GU24
<p>Drs. Neeraj Agarwal and Jeanny Aragon-Ching discuss several key abstracts to be presented at the 2024 ASCO GU Cancers Symposium, including sequencing versus upfront combination therapies for mCRPC in the BRCAAway study, updates on the CheckMate-9ER and CheckMate-214 trials in ... Show More
25m 10s